BTK inhibitors, such as ibrutinib, acalabrutinib, and zanubrutinib, inhibit BTK and dependent pathways, thereby reducing CLL cell survival [7]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.